Biotech & Healthcare Analysts, along with Dr. Darrel Cohen, CMO of VIRX and Dr. Joshua Kra of Rutgers Cancer Institute, discuss the unmet need and potential treatment of EBV-associated cancer on an Analyst/Industry conference call to be held on February 15 at 1 pm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIRX:
- Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
- Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Viracta Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
- Viracta Therapeutics provides anticipated 2024 milestones
- Viracta Therapeutics Provides Clinical Update and Outlook for 2024
